Article info

Download PDFPDF
CP-061 Long-term cost-effectiveness analysis of infliximab, etanercept and adalimumab in rheumatoid arthritis patients in real-life clinical practice

Authors

Citation

Cardenas M, Font P, De La Fuente-Ruiz S, et al
CP-061 Long-term cost-effectiveness analysis of infliximab, etanercept and adalimumab in rheumatoid arthritis patients in real-life clinical practice

Publication history

  • First published March 24, 2015.
Online issue publication 
March 24, 2015

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.